Plasma fractionation is a process of separating various components of
plasma, which in turn is a component of blood obtained through blood
fractionation. Plasma is separated and can be used for many different
medical applications. Plasma is taken from donors when whole blood is
donated, or by plasmapheresis - a process by which the liquid part of
the blood, or plasma, is separated from the blood cells and plasma is
retained. This plasma can be used as Fresh Frozen Plasma (FFP) for
replacement of clotting factors. Most plasma is used for products
which derived from plasma fractionation. Plasma comprehends thousands
of diverse proteins, but only about 20 of these are used to produce
therapeutic plasma products. These fit into three classes’
immunoglobulins, clotting factors, and albumin.
Growth of this market is mainly attributed to increasing incidence of
bleeding and immune disorders, growing geriatric population, and
growing use of immunoglobulin and alpha-1-antitrypsin. Plasma
fractionation is used for treating protein deficiency in healthcare
applications and also as a packaging material for industrial
applications. The prime function of plasma fractionation is removal
or inactivation of viruses and prions.
According to Centers of Disease Control (CDC) statistic, in 2012
chronic diseases were one of the major causes of death and disability
in the U.S., with an estimated 117 million people suffering from some
form of chronic disease. Developed diagnostic facilities, and comfort
of access to healthcare along with increasing incidence and
prevalence of chronic diseases all over the world, are some factors
responsible for the rising demand for plasma derived products and is
expected to drive the plasma fractionation market during the forecast
period. The increase in geriatric population all over world is an
important factor for plasma fractionation market, mainly due to the
risk of complications of hemophilia, such as intracranial hemorrhage,
inhibitor development, and joint diseases, increases along with the
age of a person.
North America is leading the global
plasma fractionation market, owing to growing per capita
healthcare spending in the U.S. And also rising demands from patients
for better and advanced healthcare facilities, and increased
acceptance of new and advanced technologies. Asia Pacific region is
also witnessing highest CAGR in the forecast period, due to factors
such as increasing prevalence of hemophilia among developing
countries such as China, and India, and increasing aging population
in the Asia Pacific region.
Global Key Klayers - Plasma Fractionation Market
Key players operating in the global plasma fractionation market are
CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated,
Octapharma AG, and Kedrion S.p.A held the major share of the plasma
fractionation market and will continue to take over the market. Other
major players are Bio Products Laboratory, Sanquin, China Biologic
Products, Inc., Biotest AG, and Laboratoire Français du
Fractionnement et des Biotechnologies.
Browse
Complete Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/plasma-fractionation-market-529
Plasma Fractionation Market
On the basis of product type, the global plasma fractionation
market is classified into:
• Albumin
• Immunoglobulins
• Coagulation Factor Concentrates
On the basis of application, the global plasma fractionation
market is classified into:
• Neurology
• Hematology
• Immunology
• Critical Care
On the basis of end user, the global plasma fractionation market
is classified into:
• Hospitals
• Clinical Research Laboratories
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
0 comments:
Post a Comment